Efficacy and Safety of JAK Inhibitors for Rheumatoid Arthritis: A Meta-Analysis

Efficacy and Safety of JAK Inhibitors for Rheumatoid Arthritis: A Meta-Analysis

Background: More and more trials have been conducted. We aimed to assess the efficacy and safety of different JAKinibs in RA. Methods: A systematic search of randomized controlled trials (RCTs) with JAKinib treatment in RA published in the Medline, Embase, and Cochrane databases up to May 2021 was p...

Full description

Bibliographic Details
Main Authors:	Faping Wang, Xiaoju Tang, Min Zhu, Hui Mao, Huajing Wan, Fengming Luo
Format:	Article
Language:	English
Published:	MDPI AG 2022-07-01
Series:	Journal of Clinical Medicine
Subjects:	rheumatoid arthritis JAK inhibitors meta-analysis systematic review
Online Access:	https://www.mdpi.com/2077-0383/11/15/4459

Similar Items

JAK inhibitors for the treatment of rheumatoid arthritis
by: Akio Morinobu
Published: (2020-10-01)

JAK ACADEMY in Rheumatoid Arthritis (RA)
by: Roberto Caporali, et al.
Published: (2018-09-01)

Different Biomarkers of Response to Treatment with Selective Jak-1 Inhibitors in Rheumatoid Arthritis
by: Maurizio Benucci, et al.
Published: (2023-08-01)

Real-Life Comparison of Four JAK Inhibitors in Rheumatoid Arthritis (ELECTRA-<i>i</i> Study)
by: Maurizio Benucci, et al.
Published: (2024-03-01)

Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study
by: Shuhei Yoshida, et al.
Published: (2023-10-01)

New insights into IFN-γ in rheumatoid arthritis: role in the era of JAK inhibitors
by: Masaru Kato
Published: (2020-04-01)

Evolution of Rheumatoid-Arthritis-Associated Interstitial Lung Disease in Patients Treated with JAK Inhibitors: A Retrospective Exploratory Study
by: Vincenzo Venerito, et al.
Published: (2023-01-01)

Characteristics of Patients Treated with JAK Inhibitors in Rheumatoid Arthritis before versus after VTE Risk Warnings
by: Cécile Philippoteaux, et al.
Published: (2022-12-01)

JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data
by: Harrington R, et al.
Published: (2020-09-01)

Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis
by: Irma Convertino, et al.
Published: (2023-03-01)

NEW APPROACHES TO PHARMACOTHERAPY OF RHEUMATOID ARTHRITIS: TOFACITINIB
by: E. L. Nasonov
Published: (2014-06-01)

Preclinical Characterization of the Selective JAK1 Inhibitor LW402 for Treatment of Rheumatoid Arthritis
by: Zhang N, et al.
Published: (2021-05-01)

Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes
by: Mark Genovese, et al.
Published: (2018-03-01)

Atomic Simulation of the Binding of JAK1 and JAK2 with the Selective Inhibitor Ruxolitinib
by: Maxim Kondratyev, et al.
Published: (2022-09-01)

Janus Kinase Inhibitors Improve Disease Activity and Patient-Reported Outcomes in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of 24,135 Patients
by: Lilla Tóth, et al.
Published: (2022-01-01)

Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis
by: Przemysław J. Kotyla, et al.
Published: (2020-10-01)

Metabolic Profiling of Rheumatoid Arthritis Neutrophils Reveals Altered Energy Metabolism That Is Not Affected by JAK Inhibition
by: Susama Chokesuwattanaskul, et al.
Published: (2022-07-01)

The progress of rheumatology in the 21st century potential uses of upadacitinib in rheumatoid arthritis and other inflammatory rheumatic diseases
by: E. L. Nasonov, et al.
Published: (2020-11-01)

New alternative in the treatment of rheumatoid arthritis: clinical utility of baricitinib
by: Kawalec P, et al.
Published: (2019-02-01)

Comparison of treatment of severe rheumatoid arthritis patients with biological agents and JAK-STAT inhibitors. An observational study
by: Małgorzata Wisłowska
Published: (2022-05-01)

Rheumatoid arthritis: achievements and unresolved issues
by: E L Nasonov, et al.
Published: (2019-05-01)

Effectiveness and safety profile of tofacitinib and baricitinib in rheumatoid arthritis patients: results from a 24-month real-life prospective study in Southern-Italy
by: M. Tasso, et al.
Published: (2022-12-01)

Tofacitinib Efficacy in Patients with Rheumatoid Arthritis and Probable Depression/Anxiety: Post Hoc Analysis of Phase 3 and 3b/4 Randomized Controlled Trials
by: Gustavo Citera, et al.
Published: (2023-11-01)

Hi-JAKi-ng Synovial Fibroblasts in Inflammatory Arthritis With JAK Inhibitors
by: Blaž Burja, et al.
Published: (2020-05-01)

Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis In Vivo and Baseline Signaling Profile Associates With Treatment Response
by: Maaria Palmroth, et al.
Published: (2021-09-01)

European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib
by: Kawalec P, et al.
Published: (2017-12-01)

Efficacy and safety of tofacitinib for immune-mediated inflammatory rheumatic diseases (Part I)
by: E. L. Nasonov, et al.
Published: (2020-02-01)

Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis
by: Samantha Sarabia, et al.
Published: (2022-09-01)

Editor’s Pick: JAK Inhibitors in the Treatment Algorithm of Rheumatoid Arthritis: A Review
by: Salvatore Bellinvia, et al.
Published: (2018-07-01)

Effectiveness and Safety of Iguratimod Monotherapy or Combined With Methotrexate in Treating Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
by: Dan Ouyang, et al.
Published: (2022-08-01)

JAK2 mutation may predict response and guide first line treatment in rheumatoid arthritis
by: Yasmin Adel, et al.
Published: (2021-12-01)

In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)
by: Julie M. Parmentier, et al.
Published: (2018-08-01)

One of the active ingredients in Paeoniae Radix Alba functions as JAK1 inhibitor in rheumatoid arthritis
by: Lu Xiao, et al.
Published: (2022-09-01)

Association between maternal rheumatoid arthritis and small for gestational age neonates: a systematic review and meta-analysis
by: Lv Tian, et al.
Published: (2023-09-01)

Effects of One-Year Tofacitinib Therapy on Lipids and Adipokines in Association with Vascular Pathophysiology in Rheumatoid Arthritis
by: Monika Czókolyová, et al.
Published: (2022-10-01)

Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain
by: Schlueter M, et al.
Published: (2019-06-01)

Filgotinib Demonstrates Efficacy in Rheumatoid Arthritis Independent of Smoking Status: Post Hoc Analysis of Phase 3 Trials and Claims-Based Analysis
by: Jeffrey R. Curtis, et al.
Published: (2023-12-01)

The Effect and Safety of Iguratimod Combined With Methotrexate on Rheumatoid Arthritis: A Systematic Review and Meta-Analysis Based on a Randomized Controlled Trial
by: Liuting Zeng, et al.
Published: (2022-01-01)

Efficacy and safety of tofacitinib combined with methotrexate in the treatment of rheumatoid arthritis: A systematic review and meta-analysis
by: Yan Gao, et al.
Published: (2023-05-01)

JAK inhibitors differentially modulate B cell activation, maturation and function: A comparative analysis of five JAK inhibitors in an in-vitro B cell differentiation model and in patients with rheumatoid arthritis
by: Natalie Frede, et al.
Published: (2023-01-01)